Phelix Therapeutics
Philadelphia
About Phelix Therapeutics
Phelix Therapeutics, LLC is dedicated to saving the lives of people diagnosed with Idiopathic Pulmonary Fibrosis, and other Fibrotic Diseases, by developing innovative treatments for these fatal conditions. Phelix Therapeutics continues to advance and commercialize the Calpain Inhibitor research and development work of Dr. Doron Greenbaum. The unique biological approach of Phelix Therapeutics relies on the insight that the connected processes of cellular injury/death and fibrosis can both be treated by inhibition of a single therapeutic target.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $201.7K
- Last round: Grant (Jan 2018)
- Website: phelixtherapeutics.com
- Phone: 215-966-6232
Industries & Categories
Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/phelix-therapeutics-2212327 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.